Introduction Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …

Since the identification of SARS-CoV-2 at the end of 2019, the coronavirus disease 2019
(COVID-19) pandemic has affected more than 410 million people worldwide and killed …

Abstract Introduction The Italian Society of Anti-Infective Therapy (SITA) and the Italian
Society of Pulmonology (SIP) constituted an expert panel for developing evidence-based …

Purpose This executive summary of a national living guideline aims to provide rapid
evidence based recommendations on the role of drug interventions in the treatment of …

COVID‐19: Interim Guidance on Management Pending Empirical Evidence. From an American
Thoracic Society‐led Int Page 1 1 Updated April 3, 2020 COVID‐19: Interim Guidance on …

2019 (COVID-19) is either indirect (from studies of influenza, severe acute respiratory
syndrome and Middle East respiratory syndrome) or from several observational studies and …

Background Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute
respiratory syndrome-coronavirus-2. Consensus suggestions can standardise care, thereby …

Abstract Scope In January 2021, the ESCMID Executive Committee decided to launch a new
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …

Methods The original version of this document was developed in consultation with the
International Forum for Acute Care Trialists (InFACT), International Severe Acute Respiratory …

Objectives: The outcomes reported in trials in coronavirus disease 2019 are extremely
heterogeneous and of uncertain patient relevance, limiting their applicability for clinical …